Pharmacist Support to Prevent Dangerous Low Blood Sugar in Type 2 Diabetes
Tests pharmacist help to prevent low blood sugar in high-risk adults.
Plain-language title generated from the registry record
Registry title: Hypoglycemia Prevention in High-Risk Type 2 Diabetes Patients
Key facts
- Where
- Pleasanton, United StatesSee the site
Where in United States
- Kaiser Permanente Department of ResearchPleasanton, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kaiser Permanente
- Trial code
- NCT06746714
- Record updated
- 14 October 2026
- Original description
Severe low blood sugar (hypoglycemia) is a serious problem for people with diabetes. It can lead to dangerous falls, heart problems, memory issues, and even death. However, many healthcare providers don't recognize or manage this problem well. The investigators believe that creating a clear set of guidelines for preventing hypoglycemia, along with having a clinical pharmacist actively help high-risk patients, can make diabetes treatment safer.Read full original descriptionShow less
Testing a New Population Management Model for Hypoglycemia Prevention in High-Risk KPNC Members
Severe low blood sugar (hypoglycemia) is a serious problem for people with diabetes. It can lead to dangerous falls, heart problems, memory issues, and even death. However, many healthcare providers don't recognize or manage this problem well. The investigators believe that creating a clear set of guidelines for preventing hypoglycemia, along with having a clinical pharmacist actively help high-risk patients, can make diabetes treatment safer.
In this study, the investigators developed a simple, evidence-based guide called "Hypoglycemia on a Page" (HOAP) to prevent low blood sugars. The investigators then tested it by comparing two groups of patients with type 2 diabetes who are at high risk for hypoglycemia. One group received active support from a clinical pharmacist using the HOAP guidelines, while the other group received standard care.
The main goal of this study is to see if the pharmacist's support leads to safer diabetes treatment. The investigators will also look at other factors, such as whether patients are prescribed glucagon (a medicine for severe low blood sugar), if they use continuous glucose monitoring, and whether they have worse blood sugar control or end up in the hospital for hypoglycemia. This trial aims to improve patient safety, health outcomes, and possibly lower healthcare costs.
Inclusion: Active KPNC members with valid MRNs at baseline (06/01/2023),; age >=18 years,; in the KPNC diabetes registry,; likely type 2 diabetes (determined using a validated algorithm); high risk for hypoglycemia, determined using the hypoglycemia risk stratification tool developed by the investigator team.
Exclusion: receiving care at skill nursing facilities,; enrolled in concurrent pharmacy deprescribing pilots; Dementia or impaired cognition,; end-stage renal disease,; Pregnant patients; Aim 4: In addition to criteria above, participants will only include patients with type 2 diabetes (T2D) who use a CGM device, have authorized sharing of their CGM data with their healthcare provider and have evidence of "excess hypoglycemia" (>=4% TBR on continuous glucose monitor readouts); psychosis or schizophrenia diagnosis,; "no contact" preferences on file,; no primary care physician or home facility,; deceased,.